Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects

Daniel R. Kuritzkes, Christina M. Lalama, Heather J. Ribaudo, Michelle Marcial, William A. Meyer, Cecilia Shikuma, Victoria A. Johnson, Susan A. Fiscus, Richard T. D'Aquila, Bruce R. Schackman, Edward P. Acosta, Roy M. Gulick

Research output: Contribution to journalArticle

127 Scopus citations

Abstract

A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on the response to efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort of efavirenz-treated subjects plus unselected subjects who experienced virologic failure. Of 220 subjects in the random cohort, 57 (26%) had virologic failure. The prevalence of baseline NNRTI resistance was 5%. The risk of virologic failure for subjects with baseline NNRTI resistance was higher than that for subjects without such resistance (hazard ratio 2.27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)867-870
Number of pages4
JournalJournal of Infectious Diseases
Volume197
Issue number6
DOIs
StatePublished - Mar 15 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects'. Together they form a unique fingerprint.

Cite this